The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Scores machine (provisoires)
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
- Écart entre enseignants
- 0,259 · la distance entre les deux têtes enseignantes sur ce seul travail
- Statut de validation
score_only:v0-immature-baseline· tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle
Résumé
OBJECTIVE: To characterize rates of regional Alzheimer disease (AD)-specific brain atrophy across the presymptomatic, mild cognitive impairment, and dementia stages. DESIGN: Multicenter case-control study of neuroimaging, cerebrospinal fluid, and cognitive test score data from the Alzheimer's Disease Neuroimaging Initiative. SETTING: Research centers across the United States and Canada. PATIENTS: We examined a total of 317 participants with baseline cerebrospinal fluid biomarker measurements and 3 T1-weighted magnetic resonance images obtained within 1 year. MAIN OUTCOME MEASURES: We used automated tools to compute annual longitudinal atrophy in the hippocampus and cortical regions targeted in AD. We used Mini-Mental State Examination scores as a measure of cognitive performance. We performed a cross-subject analysis of atrophy rates and acceleration on individuals with an AD-like cerebrospinal fluid molecular profile. RESULTS: In presymptomatic individuals harboring indicators of AD, baseline thickness in AD-vulnerable cortical regions was significantly reduced compared with that of healthy control individuals, but baseline hippocampal volume was not. Across the clinical spectrum, rates of AD-specific cortical thinning increased with decreasing cognitive performance before peaking at approximately the Mini-Mental State Examination score of 21, beyond which rates of thinning started to decline. Annual rates of hippocampal volume loss showed a continuously increasing pattern with decreasing cognitive performance as low as the Mini-Mental State Examination score of 15. Analysis of the second derivative of imaging measurements revealed that AD-specific cortical thinning exhibited early acceleration followed by deceleration. Conversely, hippocampal volume loss exhibited positive acceleration across all study participants. CONCLUSIONS: Alzheimer disease-specific cortical thinning and hippocampal volume loss are consistent with a sigmoidal pattern, with an acceleration phase during the early stages of the disease. Clinical trials should carefully consider the nonlinear behavior of these AD biomarkers.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Archives of Neurology
- Thématique
- Dementia and Cognitive Impairment Research
- Domaine
- Medicine
- Établissements canadiens
- —
- Organismes subventionnaires
- Avid RadiopharmaceuticalsGenentechNational Institutes of HealthNational Institute of Biomedical Imaging and BioengineeringUniversity of California, Los AngelesIpsenTel Aviv UniversityEisaiBayer HealthCareMultiple Sclerosis SocietyKorean Neurological AssociationNorthern California Institute for Research and EducationMcGill UniversityNational Institute of Neurological Disorders and StrokeUniversity of PittsburghU.S. Social Security AdministrationJohns Hopkins UniversityAssistance publique-Hôpitaux de ParisHarvard CatalystSynarcMedpaceEllison Medical FoundationWashington University in St. LouisGlaxoSmithKlineBristol-Myers SquibbU.S. Department of DefenseEli Lilly and CompanyAstraZenecaMontreal Neurological Institute and HospitalElanHarvard UniversityNational Center for Research ResourcesF. Hoffmann-La RocheYork UniversityPfizerAlzheimer's AssociationSPIENational Center for Complementary and Integrative HealthNational Institute on AgingAbbott LaboratoriesUniversity of California, San DiegoU.S. Department of Veterans Affairs
- Mots-clés
- Alzheimer's Disease Neuroimaging InitiativeAtrophyNeuroimagingHippocampal formationDementiaHippocampusBrain sizeMagnetic resonance imagingAlzheimer's diseasePsychologyNeuroscienceMedicineCerebrospinal fluidCognitionInternal medicineEffects of sleep deprivation on cognitive performanceDiseaseRadiology
- Résumé présent dans OpenAlex
- oui